ストックスクリーナーアプリを入手
1.41
4.44%
0.06
アフターアワーズ：
1.42
0.01
+0.71%
前日終値:
$1.35
開ける：
$1.34
24時間の取引高:
1.63M
Relative Volume:
1.29
時価総額：
$240.21M
収益：
$4.71M
当期純損益:
$-58.01M
株価収益率:
-1.7124
EPS:
-0.8234
ネットキャッシュフロー:
$-46.68M
1週間 パフォーマンス:
+25.89%
1か月 パフォーマンス:
+2.92%
6か月 パフォーマンス:
+11.90%
1年 パフォーマンス:
+24.78%
1日の値動き範囲:
$1.3201
$1.42
1週間の範囲:
$1.125
$1.42
52週間の値動き範囲:
$0.9495
$1.70
Lucid Diagnostics Inc Stock (LUCD) Company Profile
Compare LUCD vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LUCD
Lucid Diagnostics Inc
|
1.41 | 229.99M | 4.71M | -58.01M | -46.68M | -0.8234 |
ABT
Abbott Laboratories
|
101.56 | 175.59B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
341.24 | 132.47B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
87.10 | 113.14B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
64.61 | 94.85B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
78.20 | 45.09B | 6.07B | 1.06B | 1.34B | 1.8063 |
Lucid Diagnostics Inc Stock (LUCD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-12-27 | 開始されました | Ascendiant Capital Markets | Buy |
| 2021-11-08 | 開始されました | BTIG Research | Buy |
| 2021-11-08 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-11-08 | 開始されました | Needham | Buy |
Lucid Diagnostics Inc (LUCD) 最新ニュース
Lucid Diagnostics Outperforms Pressure BioSciences in Key Metrics - National Today
Lucid Diagnostics (LUCD) CMO holds 650K shares including restricted stock - Stock Titan
Layoff Watch: Whats the MACD signal for Lucid Diagnostics Inc2026 Analyst Calls & Long Hold Capital Preservation Plans - baoquankhu1.vn
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 13, 2025 - Quantisnow
Fed Meeting: Is Lucid Diagnostics Inc stock forming a cup and handle2026 PreEarnings & Community Consensus Picks - baoquankhu1.vn
Dividend Watch: Can Lucid Diagnostics Inc be recession proofTrade Exit Report & Precise Swing Trade Alerts - baoquankhu1.vn
Ascendiant Maintains Lucid Diagnostics(LUCD.US) With Buy Rating, Raises Target Price to $9 - Moomoo
Breakout Move: What is the next catalyst for Lucid Diagnostics Inc2026 Performance Recap & Daily Profit Maximizing Tips - baoquankhu1.vn
Lucid Diagnostics to Participate in Needham Healthcare Conference - National Today
Lucid Diagnostics to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference - Bitget
Lucid Diagnostics to Participate in Fireside Chat at Healthcare Conference - National Today
Lucid Diagnostics CEO to Participate in Healthcare Conference - Intellectia AI
Lucid Diagnostics Inc. (NASDAQ:LUCD) Q3 2025 Earnings Call Transcript - MSN
Q3 2025 PAVmed Inc Earnings Call Transcript - GuruFocus
Aug Action: Whats the MACD signal for Lucid Diagnostics Inc2026 Earnings Surprises & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
LUCD PE Ratio & Valuation, Is LUCD Overvalued - Intellectia AI
Lucid Diagnostics Inc. (LUCD) stock price, news, quote and history - Yahoo Finance UK
PAVmed Appoints New Executive to Drive Medical Device Development - Intellectia AI
PAVmed appoints Joseph Virgilio as medical device chief By Investing.com - Investing.com Canada
PAVmed Appoints Joseph Virgilio to Lead Relaunched Medical Device Portfolio - ChartMill
Lucid Diagnostics Inc. (NASDAQ:LUCD) Short Interest Update - MarketBeat
Dow Update: Can Lucid Diagnostics Inc be recession proof2026 Key Highlights & Accurate Intraday Trade Tips - baoquankhu1.vn
Lucid Diagnostics’ Earnings Call: Momentum Amid Cash Strain - The Globe and Mail
LUCD: BTIG Reiterates Buy Rating with $2.50 Price Target | LUCD Stock News - GuruFocus
Profit Review: Whats the MACD signal for Lucid Diagnostics Inc2026 Trends & Scalable Portfolio Growth Ideas - baoquankhu1.vn
PAVmed Reports 2025 Financial Results, Strengthens Capital Structure, and Expands Medical Device Portfolio Under New Leadership - Minichart
BTIG reiterates Lucid Diagnostics stock rating on Q4 beat By Investing.com - Investing.com South Africa
Lucid Diagnostics (NASDAQ:LUCD) Earns Buy Rating from BTIG Research - MarketBeat
PAVmed (NASDAQ: PAVM) overhauls capital structure and reports 2025 results - Stock Titan
Lucid Diagnostics (LUCD) Earnings Transcript - AOL.com
PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results - MarketScreener
BTIG reiterates Lucid Diagnostics stock rating on Q4 beat - Investing.com
Lucid Diagnostics Inc. (LUCD) reports Q4 loss, beats revenue estimates - MSN
PAVmed Restructures Capital and Relaunches Product Line - Intellectia AI
Lucid Diagnostics non-GAAP adjusted loss hits USD 12.6M in Q4 2025 - Medical Buyer
Lucid Diagnostics (NASDAQ:LUCD) Rating Increased to Hold at Wall Street Zen - MarketBeat
Valuation Update: What is the long term forecast for Lucid Diagnostics Inc stockQuarterly Trade Review & Stepwise Trade Execution Plans - baoquankhu1.vn
PAVmed (PAVM) outlines going concern risk, Nasdaq compliance and growth plans - stocktitan.net
Lucid Diagnostics (NASDAQ:LUCD) Issues Earnings Results, Misses Estimates By $0.03 EPS - MarketBeat
Lucid Diagnostics Inc. (NASDAQ:LUCD) Q4 2025 Earnings Call Transcript - Insider Monkey
[EFFECT] Lucid Diagnostics Inc. SEC Filing - Stock Titan
Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results - StreetInsider
Lucid Diagnostics Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:LUCD) 2026-03-27 - Seeking Alpha
Lucid Diagnostics Reports 2025 Financial Results, Expands EsoGuard Access with VA Contract and Positive Real-World Data - Minichart
Lucid Diagnostics reports Q4 revenue of $1.5M, VA contract By Investing.com - Investing.com South Africa
Lucid Diagnostics signals expanded VA market access and 29% sequential test volume growth while targeting Medicare and commercial payer wins - msn.com
Lucid Diagnostics (NASDAQ: LUCD) launches ATM program to sell up to $25M - Stock Titan
Lucid Diagnostics Inc (LUCD) Q4 2025 Earnings Call Highlights: Strong Test Volume Growth and ... By GuruFocus - Investing.com Canada
Lucid Diagnostics Reports Q4 2025 Results, Highlights VA Contract - TipRanks
Needham reiterates Buy on Lucid Diagnostics stock, $3 target By Investing.com - Investing.com Australia
The Dixie Group Q4 2025 Financial Review - AlphaStreet
Lucid Diagnostics Inc (LUCD) 財務データ
収益
当期純利益
現金流量
EPS
2.40%
0.00%
大文字化:
|
ボリューム (24 時間):